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Abstract The acridinone derivatives with antitumor
activity and ability with respect to noncovalent DNA
binding were investigated for their quantitative structure–
activity relationships (QSAR). Multiple regression analysis
was used to model relationships between molecular
descriptors and antileukemia activity, or between molecu-
lar descriptors and DNA-duplexes stabilization. Studies
were performed on molecular modeling using HyperChem
and Dragon computer programs, and molecular geometry
optimization using MM? molecular mechanics and semi-
empirical AM1 method. Two multiple regression equations
were derived and characterized as good and with statisti-
cally significant correlations, R = 0.9384 and R = 0.8388,
for quantitative structure–antitumor activity relationships
and quantitative structure–ability to DNA-duplexes stabil-
ization relationships, respectively. Moreover, hydrophobic
and total molecular symmetry properties are important for
antitumor activity of acridinone derivatives, and electronic
and topological properties are important for physico-
chemical (noncovalent) DNA-duplexes stabilization of
these compounds. The obtained equations can be used for
prediction of acridinone derivatives’ activity and their
ability to noncovalent interaction with DNA which, as it
was shown earlier, play important role in the antitumor
mechanism of action of these compounds.
Keywords Quantitative structure–activity
relationships (QSAR)  Multiple linear regression (MLR)
analysis  Acridinones  Antitumor activity 
Physicochemical interaction with DNA
Introduction
The acridinones represented by imidazo- and triazolo-
acridinones are a new group of potent antitumor compounds
(Cholody et al., 1990, 1992, 1996) from which one of the
most active derivatives called as C-1305 has been selected
for extended preclinical trials and the other one called
C-1311 (for review see Mazerska et al., 1998) is currently
undergoing phase II clinical trials as drug SymadexTM
(Burger et al., 1996; Den Brok et al., 2005a, b, c). Imi-
dazoacridinones exhibit in vivo activity against various
tumor cell lines as leukemia, melanoma, colon adenocarci-
noma, and colon carcinoma. Triazoloacridinones exhibit
in vivo activity against leukemia, murine carcinoma, lung
carcinoma, breast carcinoma, and colon carcinoma (Chol-
ody et al., 1990, 1992, 1996; Kusnierczyk et al., 1994;
Burger et al., 1996a, b; Lamb and Wheatley, 1996; Cala-
brese et al., 1998, 1999; Alami et al., 2007; De Marco et al.,
2007; Bram et al., 2007). As was previously shown
(Składanowski et al., 1999; Lemke et al., 2004; Augustin
et al., 2004, 2006; Wesierska-Gadek et al., 2004; Koba and
Konopa, 2007; Koba et al., 2009), cellular DNA is important
target for the triazoloacridinone drugs, and hence interac-
tions with DNA are naturally the crucial point in view of the
biological activity of these compounds. In previous article
(Składanowski et al., 1999; Lemke et al., 2004), it was
indicated that triazoloacridinones inhibit cleavable com-
plexes of topoisomerase II with DNA. They inhibit also
nucleic acid or protein synthesis induced by G2 block of cell
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cycle followed by apoptosis (Augustin et al., 2004, 2006;
Wesierska-Gadek et al., 2004), intercalating to DNA and
binding in minor groove (Koba and Konopa, 2007; Koba
et al., 2009) and/or forming of interstrand DNA crosslinks
(Koba and Konopa, 2007). In addition, it was shown that
intercalation to DNA takes place preferentially in guanine
triplet regions inducing changes in DNA structures (Lemke
et al., 2005). For imidazoacridinones, it was demonstrated
that intercalation to DNA undergoes at physiological con-
dition with parallel stabilization of double-stranded DNA
and unwinding of supercoiled DNA (Burger et al., 1999;
Dziegielewski et al., 2002). The intercalative binding mode
of acridinone derivatives was also confirmed with the use of
molecular-modeling studies (Mazerski and Muchniewicz,
2000). Similar to other DNA-binding agents, treatment of
tumor cells with imidazoacridinones induces topoisomerase
II-associated DNA strand breaks (Składanowski et al.,
1996), arrests cells in G2 phase, and stimulates apoptosis
(Zaffaroni et al., 2001; Skwarska et al., 2007) or mitotic
catastrophe (Hyzy et al., 2005; Skwarska et al., 2007).
However, after testing imidazoacridinone and triazolo-
acridinone derivatives, it has been concluded that although
the intercalative binding to DNA seems to be necessary for
their biological activity (the most active compounds have
usually the highest binding affinity), it is not sufficient (some
inactive analogs also bind strongly with DNA) (Dziegie-
lewski et al., 2002; Koba and Konopa, 2007). Moreover,
acridinones undergo enzymatic oxidation, and this reaction
is important for their biological activity as intercalation to
DNA and covalent adducts formation (Dziegielewski and
Konopa, 1996; Mazerska et al., 1999, 2003). In this context,
noncovalent interaction of acridinones may help position
drug molecules on DNA for the covalent reaction.
In this article, physicochemical interactions of acridinones
with DNA were evaluated in view of quantitative structure–
activity relationships (QSAR). Multiple regression analysis
was used to model relationships between molecular structural
descriptors and biological (antitumor) activity of molecules,
or between molecular structural descriptors and physico-
chemical interaction of acridinone derivatives with DNA.
The biological data expressed as anti-leukemia P388 activity
and parameter describing ability to physicochemical (non-
covalent) interaction with DNA as value of DNA-duplexes
stabilization were applied in this study.
Materials and methods
Antitumor and physicochemical DNA-binding activity
data of acridinones
The acridinone derivatives examined in this study have
been selected to collect analogue compounds differing in
chemical structures as well as anticancer activities
(Table 1). The data of acridinones’ antitumor activity
against P388 leukemia in mice in vivo and expressed as the
percentage of increase in survival time of the treated to that
of the control mice with P388 leukemia at optimal dose
(ILS) were taken from the literature (Table 1) (Cholody
et al., 1990, 1992; Koba and Konopa, 2007; Mazerska
et al., 1996). The data of physicochemical binding of
acridinones to DNA (as values of DNA-duplexes stabil-
ization), which were expressed as an increase in DNA
melting temperature in centigrade degrees of ctDNA at
drug to DNA base pairs 0.25 M ratio were taken from the
literature (Table 1) (Koba and Konopa, 2007; Dziegie-
lewski et al., 2002).
Structural parameters
The structure of the tested compounds was studied by
molecular modeling using HyperChem 7.5 Release soft-
ware (Kaliszan et al., 1995; Ivanciuc, 1996) and Dragon
software (Todeschini et al., 2000). The structures of the
compounds were first pre-optimized with the Molecular
Mechanics Force Field (MM?) procedure included in the
Hyperchem 6.03 (Hypercube) http://www.hyper.com, and
the resulting geometries were further refined by means
of the Semi-Empirical Molecular Orbitals Method AM1
using the Polak-Ribiere algorithm and a gradient norm
limit of 0.01 kcal A˚-1.
The following molecular descriptors taken from
HyperChem software were considered among quantum and
chemical indices: total energy (TE), binding energy (BE),
isolated atomic energy (IAE), electron energy (EE), core–
core energy (CCE), heat flow (HF), energy of the highest
occupied molecular orbitals (E_HOMO), energy of the
lowest unoccupied molecular orbitals (E_LUMO), and
difference between HOMO and LUMO energies referred to
as EG = energy gap; ionization energy (potential) (IE) and
electron affinity (EA) were calculated as a difference
between the HF of positive molecular ion and electrically
neutral molecule, and electronegativity (EN) calculated as
average arithmetic potential of ionization and EA. In
addition, other parameters were used as the value of elec-
tron density of atom orbitals from the lowest to the highest
(ED_MIN and ED_MAX, respectively), the highest posi-
tive electron charge on the atoms (MAX_POS), and the
highest negative electron charge on the atoms (MAX_-
NEG), the difference between the highest positive and
negative charge (DELTA_Q), distribution of dipolar
moment along x, y, and z axes (X_DM, Y_DM, and Z_DM,
respectively), total dipolar moment (TDM), mean polariz-
ability of molecules (in atom units) MP (Mean Polariz-
ability), energy equal to the length of the wave with the
greatest long-wave transfer of electrons, for which the
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value of oscillator force was different from zero (EL)—the
value of wave figures were converted to eV—and the value
of the most intensive electron transfer (EMAX—the max-
imum value of oscillator force calculated with the use of
AM1 method—as well as oscillator maximum force used
for the transfer (OS_EMAX). Moreover, additional
parameters were calculated with the use of QSAR Prop-
erties Module of HyperChem. They include the following
descriptors: surface area of the molecule available for
solvent (SA), molecule volume (V), hydration energy (HE),
the calculated distribution coefficient logarithm (logP),
refraction (R), and polarizability (P).
On the other hand, using Dragon software, over 1,300
molecular descriptors were calculated and considered for
QSAR analysis. They include molecular parameters from
different group and class of descriptors as constitutional,
topological, walk and path counts, connectivity indices,
information indices, 2D autocorrelations, edge adjacency
indices, topological charge indices, eigenvalue-based
indices, geometrical, 3D-MoRSE, WHIM, GETAWAY,
functional group counts, atom-centred fragments, charge,
molecular properties and other group of descriptors, and
describing some properties of compound as geometry,
symmetry, topology, electronic, steric or thermodynamic
and other properties. The definitions of these descriptors
are reviewed by Todeschini (Todeschini et al., 2000).
Statistical analysis
The statistical QSAR analysis was performed with the use
of stepwise regression analysis that used Statistica 8.0
software (StatSoft, Tulsa, OK, USA). The objective of
stepwise regression is to construct a multivariate regression
model (QSAR equation) for a certain property, y, based on
several selected explanatory variables. In stepwise regres-
sion, the first selected explanatory variable has the highest

















Compound X n R1 R2 R3 R4 R5 R6 ILS
a DTm
b
C-1310 C 2 CH2CH3 CH2CH3 OH H CH3 H 185 15.3
C-1311 C 2 CH2CH3 CH2CH3 OH H H H 93 13.7
C-1330 C 2 CH2CH3 CH2CH3 OCH3 H H H 96 11.5
C-1415 C 2 CH2CH3 CH2CH3 H H H H 55 7.2
C-1419 C 2 CH2CH3 CH2CH3 H H H OH 27 8.3
C-1558 C 2 CH2CH3 CH2CH3 C(CH3)3 H H H 0 2.4
C-1176 C 2 CH3 CH3 H H H H 90 9.5
C-1263 C 2 CH3 CH3 OH H H H 110 12.3
C-1212 C 3 CH3 CH3 H H H H 25 11.5
C-1371 C 3 CH3 CH3 OH H H H 120 3.5
C-1554 C 5 CH2CH3 CH2CH3 CH3 H H H 20 10.5
C-1266 C 5 CH3 CH3 H H H H 10 9.9
C-1492 C 5 CH3 CH3 OH H H H 85 13.1
C-1233 N 2 CH3 CH3 H H – H 77 9.1
C-1303 N 2 CH3 CH3 OH H – H 102 13.1
C-1533 N 2 CH3 CH3 OH CH3 – H 10 8.1
C-1567 N 2 CH3 CH3 C(CH3)3 H – H 0 6.8
C-1410 N 2 H CH2CH3 OH H – H 78 7.1
C-1296 N 3 CH3 CH3 CH3 H – H 18 11.5
C-1305 N 3 CH3 CH3 OH H – H 165 15.1
a The percentage of increase in survival time of treated to control mice with P388 leukemia at optimal dose
b The increase in DNA melting temperature (expressed in centigrade degrees) at drug to DNA base pairs 0.25 M ratio
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correlation with dependent variable, y. Then, explanatory
(independent) variables are consecutively added to the
model in a forward selection procedure. A new variable is
added to the model if a significant change in residuals of
the model can be observed. The significance is evaluated
using a statistical test, usually F-test (the value of the F-test
of significance, F). In addition, the multiple correlation
coefficients (R), the standard error of estimate (S), and the
significance levels of each term and of whole equation
(p) are calculated for the derived QSAR equations.
Whenever a new variable is included into a model, a
backward elimination step follows in which an F-test
detects the earlier selected variables, which can be
removed from the model without any significant change on
the level of the residuals. The variable selection procedure
stops when no additional variable significantly improves
the model. Stepwise regression is very much popular in
QSAR studies, since the stepwise procedure is simple and
based on the classical multiple linear regression (MLR)
approach. Moreover, it is implemented in almost all the
statistical software packages. One of the drawbacks of the
method is the fact that no optimal variable selection is
guaranteed, since the new variables are found based on the
previously included variables into the model (Put et al.,
2006).
During model building, the model fit can be improved
proportional to the model complexity. Therefore, the more
the factors are included into the model, the better the model
fits the training data. Usually, the model fit is evaluated by
the root mean-squared error (RMSE), computed for the
training data.
The determination of the optimal complexity of the
model requires an estimation of its predictive ability, to
prevent overfitting to the calibration data. After all, the
main goal of QSAR models is to obtain a reasonable pre-
diction of the retention for future samples. To evaluate the
prediction by means of an internal validation procedures,
cross validation can be used. The predictive ability of a
model is characterized by the cross-validated root mean-
squared error (RMSECV); test values were calculated with
the Matlab software (MathWorks, Natick, MA, USA). The
RMSECV as values, which quantify the predictive power
of the QSAR model, were calculated by the leave-one-out
method and leave-ten-out method.
Results and discussion
The chemical structures of the 20 compounds considered for
this study and their antitumor and noncovalent DNA-bind-
ing activities are presented in Table 1. In this study, QSAR
analysis using multiple regression method was performed
for biological activity data (ILS) or physicochemical inter-
action with DNA (DTm), and non-empirical parameters
(molecular descriptors). Owing to a large number of non-
empirical parameters (over 1,300), treated as independent
variables and according to QSAR strategy and multi-
parameter regression rule in derived multi-parameter
regression equation, the number of independent variables
must be 5–6 times less than the number of cases considered
in this study. In practice, for obtaining statistically signifi-
cant equation, one independent variable (in our case struc-
tural descriptor) falls, generally out of five to maximum six
cases considered, in dependent-variable activity (in our case,
activity of acridinones). In the research done, the data set of
20 acridinone derivatives (dependent variables) was taken to
QSAR analysis, and for this reason the derived QSAR
equations were maximally limited to four statistically sig-
nificant independent variables (structural descriptors).
Moreover, correlations were limited to the value of
regression coefficient R C 0.8 and an additional criterion,
considered as relevant to particular independent variables,
was established at the significance level p B 0.05.
The calculated equations are presented in Table 2 and
characterized by four statistically significant independent
variables with a good value of regression coefficient R C 0.8
(R = 0.9384 and R = 0.8388 for quantitative structure–anti-
tumor activity relationships and quantitative structure–ability
to DNA-duplexes stabilization relationships, respectively).
Moreover, all the regression coefficients are highly statisti-
cally significant (p \ 0.05) as is the whole equation
(p \ 7 9 10-4 for quantitative structure–antitumor activity
relationships and p \ 9 9 10-7 for quantitative structure–
ability to DNA-duplexes stabilization relationships, respec-
tively). The values of the multiple correlation coefficient,
R; the standard error of the estimate, s; and the value of the
F-test of significance, F, are also statistically significant.
Statistically significant parameters used in QSAR anal-
ysis (values of molecular descriptors are presented in the
Table 3) as logarithm of theoretically calculated n-octanol–
water partition coefficient (logP) from the class of hydro-
phobic descriptors, 3st component symmetry directional
WHIM index weighted by atomic masses (G3m), 2st
component symmetry directional WHIM index by atomic
polarizabilities (G2p), and 3st component symmetry
directional WHIM directional index/weighted by atomic
polarizabilities (G3p) from class of WHIM (Weighted
Holistic Invariant Molecular) descriptors had the influence
upon antitumor activity of acridinones. The WHIM
descriptors are molecular descriptors based on statistical
indices calculated on the projections of the atoms along
principal axes. They are built in such a way as to capture
relevant molecular 3D information regarding molecular
size shape, symmetry, and atom distribution with respect
to invariant reference frames (Todeschini et al., 2000).
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In general, the obtained data indicate that hydrophobic and
total molecular symmetry properties are important for
antitumor activity of acridinones. These observations are in
partial agreement with the data obtained by Mazerska
(Mazerska et al., 1996), for which antitumor activity of
imidazoacridinones is dependent on lipophilicity. How-
ever, impact of lipophilicity on the biological activity of
these compounds was observed only in the case of deriv-
atives with 8-hydroxyl group, which undergo metabolic
activation (Mazerska et al., 1999, 2003). Moreover,
non-hydroxyl or 9-hydroxyl derivatives also exhibited
lipophilic properties, but its effect was not crucial when
metabolic activation did not occur. Relocation of hydroxyl
group from position 8 to 9 drastically decreases antitumor
activity (C-1311 8-hydroxyl, C-1419 9-hydroxyl). In
addition, hydrophobic properties of acridinones can play
important role in transport and accumulation of these
compounds in cells in view of fastening of metabolic
activation (Składanowski et al., 1996). On the other hand,
diaminoalkyl side chain has also crucial influence on
antitumor activity of acridinones. For compounds without
8-hydroxyl group, the increase in number of carbon atoms
between nitrogen atoms from two to three or five (C-1415,
C-1176, and C-1233 two; C-1212 and C-1296 three; and
C-1266 five) generally decreases antitumor activity of























































































































































































































































































































































































































































































Table 3 Values of molecular descriptors used in QSAR analysis
Compound Molecular descriptors
GATS7e li H-047 Mp G3m logP G2p G3p
C-1310 1.07 3.70 13 0.66 0.16 -1.98 0.15 0.15
C-1311 0.92 3.06 16 0.66 0.15 -2.19 0.15 0.15
C-1330 1.19 3.16 16 0.66 0.15 -2.15 0.15 0.15
C-1415 0.90 2.32 14 0.67 0.15 -1.16 0.15 0.15
C-1419 0.89 2.01 13 0.66 0.15 -2.19 0.15 0.16
C-1558 2.13 2.28 13 0.65 0.15 0.15 0.15 0.15
C-1176 0.94 2.50 16 0.68 0.16 -1.12 0.16 0.16
C-1263 0.90 3.34 15 0.67 0.16 -2.87 0.16 0.16
C-1212 1.01 2.61 16 0.67 0.16 -1.79 0.16 0.16
C-1371 0.94 2.11 15 0.67 0.15 -2.82 0.15 0.15
C-1554 0.83 2.66 13 0.66 0.15 -1.01 0.15 0.15
C-1266 0.86 2.60 13 0.66 0.15 -0.95 0.15 0.16
C-1492 0.86 3.10 15 0.66 0.15 -1.97 0.15 0.15
C-1233 0.99 2.99 16 0.68 0.17 -1.12 0.17 0.16
C-1303 0.87 2.48 15 0.67 0.16 -2.14 0.16 0.16
C-1533 0.91 1.11 15 0.67 0.16 -1.78 0.17 0.16
C-1567 2.15 3.53 15 0.66 0.15 0.2 0.15 0.15
C-1410 0.86 2.39 11 0.67 0.16 -2.16 0.16 0.16
C-1296 0.94 3.08 19 0.67 0.16 -1.06 0.17 0.16
C-1305 0.81 2.44 18 0.67 0.17 -2.09 0.16 0.16
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bearing 8-hydroxyl group, the increase in number of carbon
atoms (C-1311, C-1263 two, C-1371 three, and C-1492
five) rather do not augment antitumor activity for imi-
dazoacridinones, while good increase in antitumor activity
is observed in case of triazoloacridinones (C-1303, C-1410
two, and C-1305 three carbon atoms). These observations
indicate that length and conformation of diaminoalkyl side
chain attached to flat aromatic acridinone ring have some
influence on proper conformation of acridinone derivatives
molecule and is in accordance with earlier modeling
studies (Mazerski and Muchniewicz, 2000) The observa-
tions also proved our suggestion that total molecular
symmetry properties in context of interaction with DNA as
intercalation and DNA groove binding are crucial for
antitumor activity of acridinones.
On the other hand, statistically significant parameters—
values of molecular descriptors are presented in the
Table 3—such as dipole moment (li) from class of elec-
tronic descriptors, mean atomic polarizability scaled on
carbon atom (Mp) from class of constitutional descriptors,
Geary autocorrelation-lag 7 weighted by atomic Sanderson
electronegativities (GATS7e) from class of 2D autocorre-
lations descriptors, and H attached to C1(sp3)/CO(sp2)
(H-047) from class of atom-centered fragments descriptors
had the influence upon physicochemical (noncovalent)
DNA-duplexes stabilization of acridinone derivatives. The
obtained data indicate that electronic and topological
properties are important for noncovalent DNA-duplexes
stabilization of these compounds. It is known that drug–
DNA binding induces changes in DNA structure and
topology and is closely connected with conformation of
drug molecule and its electronic and topological properties.
The presence of a hydroxyl group in position 8 of acridi-
none ring slightly increases the affinity for DNA compared
to unsubstituted or alkyl-substituted derivatives, possibly
because of additional hydrogen bonds with the DNA
phosphate backbone. As it was mentioned earlier (Mazer-
ski and Muchniewicz, 2000), the charged diaminoalkyl
side chain of acridinone compounds can interact with DNA
in the minor groove, in addition to intercalation. In addi-
tion, some other data (Koba and Konopa, 2007) indicated
that intercalation is not involved in stabilization of sec-
ondary structure of DNA. However, for the biologically
non-active compounds, C-1558 and C-1567, bearing a t-
butyl group in position 8, the DTm values were 2.4 and
6.8C, respectively, indicating that stabilization of the
DNA duplex by these compounds especially by C-1567
probably derived from electrostatic interactions of the side
chain with DNA and not from its intercalation to DNA.
This means that intercalation to DNA is necessary for the
biological activity of acridinones via positioning the drug
molecules within DNA before the covalent reaction and
formation of interstrand DNA crosslink (Koba and Konopa,
2007). This also indicated that topological and electronic
properties of acridinone derivatives are important for their
physicochemical interactions with DNA. Moreover, the
molecular modeling studies (Mazerski and Muchniewicz,
2000) evidenced that when acridinone C-1311 is interca-
lated between GC, the highly reactive position 8 on
acridinone core is in close proximity to nucleophilic N7
position on guanine. It is plausible to postulate that drug
molecule first intercalates into DNA and then, after in situ
activation, binds covalently to the neighboring base. These
observations are compatible with recent findings demon-
strating that electrochemically activated C-1311 forms
covalent adducts with deoxyguanine (Mazerska et al.,
2003). On the other hand, the structure of acridinones
suggests that there are at least two possible sites for
enzymatic oxidation/activation, which potentially could be
involved in the covalent binding to DNA. One is the
diaminoalkyl side chain at position 5 which is necessary for
covalent binding of mitoxantrone to DNA (Składanowski
and Konopa, 2000). The other one is the potential quinone–
imine group formed by hydroxyl group in position 8
Table 4 Values of experimental and calculated data for DNA-
duplexes stabilization and antitumor activity of acridinones
Compound DTm exp.
a DTm calc. D
b ILS exp.c ILS calc. D
C-1310 15.3 12.6 2.7 185 172 13
C-1311 13.7 13.6 0.1 93 90 3
C-1330 11.5 12.1 0.6 96 89 7
C-1415 7.2 8.8 1.6 55 53 2
C-1419 8.3 8.7 0.4 27 43 16
C-1558 2.4 2.8 0.4 0 5 5
C-1176 9.5 8.9 0.6 90 46 44
C-1263 12.3 12.5 0.2 110 110 0
C-1212 11.5 10.2 1.3 25 70 45
C-1371 3.5 8.5 5.0 120 113 7
C-1554 10.5 11.1 0.6 20 47 27
C-1266 9.9 10.7 0.8 10 -2 8
C-1492 13.1 13.5 0.4 85 82 3
C-1233 9.1 10.0 0.9 77 88 11
C-1303 13.1 10.1 3.0 102 83 19
C-1533 8.1 5.7 2.4 10 23 13
C-1567 6.8 6.3 0.5 0 3 3
C-1410 7.1 7.3 0.2 78 84 6
C-1296 11.5 14.0 2.5 18 -3 15
C-1305 15.1 12.3 2.8 165 170 5
Mean value of D 1.4 13
a The increase in DNA melting temperature (expressed in centigrade
degrees) at drug to DNA base pairs 0.25 M ratio
b Difference between experimental and calculated values
c The percentage of increase in survival time of treated to control
mice with P388 leukemia at optimal dose
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(8-OH) and heterocyclic nitrogen atom in acridinone
nucleus (Mazerska et al., 2003). Recently proposed
mechanism of oxidation involves highly unstable carbo-
cations generated in these two positions (Mazerska et al.,
2003). It is suggested that C-1311 carbocations react
rapidly with nucleophiles present in the environment,
including DNA bases forming covalent adducts. These
observations indicate that topological and electronic
properties of acridinone derivatives are also important for
their covalent interactions with DNA.
Moreover, the calculated values of ILS and DTm obtained
for other compounds (Table 4) and the plots of the experi-
mental data versus the calculated data (Fig. 1a–b) for
DNA-duplexes stabilization of acridinones expressed as
DTm (the increase in DNA melting temperature at drug to
DNA base pairs 0.25 M ratio) and antitumor activity of
acridinones expressed as ILS (survival time of treated to
control mice with P388 leukemia at optimal dose) proved
good correlation and predictive potency of proposed QSAR
models. In addition, the RMSECV as value, which quantifies
the predictive power of the proposed QSAR model, are
calculated by the leave-one-out and the leave-ten-out
methods and presented in the Table 5. The obtained values
of RMSECV test (22.79 and 22.27 for quantitative struc-
ture–antitumor activity relationships as well as 2.39 and 2.41
for quantitative structure–ability to DNA-duplexes stabil-
ization relationships) performed for all the four statistically
significant independent variables proved the predictive
power of the derived QSAR models.
Conclusions
Statistically significant equations describing structure–
antitumor activity relationships and structure–ability to
physicochemical (noncovalent) interaction with DNA
relationships in acridinone derivatives group were derived.
It has been found that hydrophobic and total molecular
symmetry properties are important for antitumor activity of
acridinone derivatives, and electronic and topological
properties are important for physicochemical (noncovalent)
DNA-duplexes stabilization of these compounds.
Fig. 1 Correlation between the experimental data and the calculated
data from the derived multiple regression QSAR equation for a DNA-
duplexes stabilization of acridinones expressed as DTm (the increase
in DNA melting temperature at drug to DNA base pairs 0.25 M ratio)
and b antitumor activity of acridinones expressed as ILS (survival
time of treated to control mice with P388 leukemia at optimal dose)
Table 5 Values of the cross-validated root-mean-square error RMSECV test
QSAR model for dependent variable RMSECV test
Leave-one-out method Leave-ten-out method
1a 2 3 4 1 2 3 4
DTm 3.36 2.53 2.56 2.39 3.44 2.63 2.64 2.41
ILS 53.39 42.10 28.48 22.79 54.23 42.35 28.74 22.27
a 1–4 represents RMSECV test performed only for one, combined two and three, and for all the four significance descriptors in QSAR models,
respectively. In the case of QSAR model, for DTm as dependent-variable values, 1–4 were obtained for only GATS7e, GATS7e combined with
li, GATS7e combined with li and H-047, GATS7e combined with li, H-047, and Mp descriptors. In the case of QSAR model for ILS as
dependent-variable values, 1–4 were obtained for only G3m, G3m combined with logP, G3m combined with logP and G2p, and G3m combined
with logP, G2p and G3p descriptors
Med Chem Res (2011) 20:1385–1393 1391
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